EULAR Points to Consider for the Diagnosis and Management of Rheumatic Immune-Related Adverse Events Due to Cancer Immunotherapy With Checkpoint Inhibitors
Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/annrheumdis-2020-217139
Full Text
Open PDFAbstract
Available in full text
Date
April 23, 2020
Authors
Publisher
BMJ